Last reviewed · How we verify
NCT07344311
A Phase I Trial of A-CAR032 in Participants With mCRPC
Phase 1 trial testing dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection in Prostate Cancer in 27 participants. Currently enrolling.
31 January 2027
Quick facts
| Lead sponsor | Shanghai AbelZeta Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 27 |
| Start date | 31 January 2026 |
| Primary completion | 31 January 2027 |
| Estimated completion | 31 January 2042 |
| Sites | 5 locations across China |
Drugs / interventions tested
- dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection — full drug profile →
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Metastatic Castration-Resistant Prostate Cancer — all drugs for Metastatic Castration-Resistant Prostate Cancer →
Sponsor
Shanghai AbelZeta Ltd. — full company profile →
Who can join
18 and older, male only, with Prostate Cancer or Metastatic Castration-Resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with mCRPC, who have previously progressed after ARPI treatment of prostate cancer (whether before or in the metastatic castration-resistant setting) and, in the judgment of the investigator, are ineligible for standard treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07344311
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Shanghai AbelZeta Ltd. trials
Trials by the same sponsor.
- NCT07444281 — An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Can · Phase 1 · recruiting
- NCT06590246 — A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) · Phase 1, PHASE2 · recruiting
- NCT05800977 — A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
- NCT04208646 — Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis · Phase 2 · completed
- NCT03154775 — Study of Safety and Efficacy of C-CAR011 in B-NHL Patients · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07344311 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai AbelZeta Ltd.
- Last refreshed: 15 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07344311.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing